Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
61 hedge funds and large institutions have $64M invested in Sierra Oncology, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 60 → 61 (+1)
16% less capital invested
Capital invested by funds: $76.5M → $64M (-$12.5M)
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
64% less call options, than puts
Call options by funds: $30K | Put options by funds: $83K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$5.11M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.19M |
| 3 |
AC
Armistice Capital
New York
|
+$2.55M |
| 4 |
BC
Broadfin Capital
New York
|
+$1.26M |
| 5 |
6CM
683 Capital Management
New York
|
+$597K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.17M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.22M |
| 3 |
PA
Perceptive Advisors
New York
|
-$852K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$834K |
| 5 |
Renaissance Technologies
New York
|
-$708K |
SRRA Hedge Fund Activity: Q4 2018 in Review
61 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q4 2018, worth a combined $64M — down 16% from $76.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SRRA positions and 9 closed out — a net gain of 1 holder — while 13 added to existing stakes and 19 trimmed.
The largest buyer was Mangrove Partners, adding an estimated $5.11M. The largest seller was Millennium Management, cutting an estimated $2.17M.
- 61 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q4 2018, up from 60 in Q3 2018.
- Funds reported $64M of Sierra Oncology, Inc. Common Stock stock for Q4 2018, down 16% quarter-over-quarter.
- 10 funds opened new Sierra Oncology, Inc. Common Stock positions in Q4 2018 and 9 closed out, a net change of +1 holder.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q4 2018 was Mangrove Partners, an estimated $5.11M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q4 2018 was Millennium Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q4 2018.